New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development
- 1 March 2009
- journal article
- review article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (3) , 849-862
Abstract
One-third of the world population is infected with Mycobac- terium tuberculosis (MTB) and hence at risk of developing active tuberculosis (TB). Each year, 8.8 million patients are newly diagnosed with active TB and 1.6 million patients die of TB. The rapid spread of the human immunodeficiency virus (HIV) has fueled the TB epidemic, especially in sub-Saharan Africa, where 28% of TB patients are HIV positive (176). The current first-line treatment for TB is a multidrug regimen con- sisting of rifampin, isoniazid, pyrazinamide, and ethambutol (RHZE). It must be taken for at least 6 months to achieve high cure rates (more than 95% in experimental settings).Keywords
This publication has 168 references indexed in Scilit:
- Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma ConcentrationsAntimicrobial Agents and Chemotherapy, 2008
- Impact of the Interaction of R207910 with Rifampin on the Treatment of Tuberculosis Studied in the Mouse ModelAntimicrobial Agents and Chemotherapy, 2008
- Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2008
- In Vitro Antimycobacterial Spectrum of a Diarylquinoline ATP Synthase InhibitorAntimicrobial Agents and Chemotherapy, 2007
- Location of Persisting Mycobacteria in a Guinea Pig Model of Tuberculosis Revealed by R207910Antimicrobial Agents and Chemotherapy, 2007
- Mycobacterium leprae Is Naturally Resistant to PA-824Antimicrobial Agents and Chemotherapy, 2006
- Use of Nonlinear Mixed-Effects Analysis for Improved Precision of Early Pharmacodynamic Measures in Tuberculosis TreatmentAntimicrobial Agents and Chemotherapy, 2006
- Combination Chemotherapy with the Nitroimidazopyran PA-824 and First-Line Drugs in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2006
- Genetic Basis for Natural and Acquired Resistance to the Diarylquinoline R207910 in MycobacteriaAntimicrobial Agents and Chemotherapy, 2006
- Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequenceNature, 1998